Member Login
Username:Password:
or Sign up here
Discover

MESALAZINE

(Redirected from Mesalamine)

'Mesalazine' (INN, BAN), also known as 'Mesalamine' (USAN) or '5-aminosalicylic acid' (5-ASA), is an anti-inflammatory drug used to treat inflammation of the digestive tract (Crohn's disease) and mild to moderate ulcerative colitis. Mesalazine is a bowel-specific aminosalicylate drug that is metabolized in the gut and has its predominant actions there, thereby having fewer systemic side effects.
As a derivative of salicylic acid, 5-ASA is also an antioxidant that traps free radicals, which are potentially damaging by-products of metabolism.
5-ASA is considered the active moiety of sulfasalazine, which is metabolized to it.

Contents
Formulations
Side effects
Monitoring
References
External links

Formulations


It is formulated for oral ingestion as tablets or granules, and for rectal administration as rectal suppository, suspension or enemas. It is sold under a variety of brand names (UK: Asacol, Ipocal, Pentasa & Salofalk. US: Canasa, Rowasa, Pentasa, Asacol and Lialda). The newest of these is Lialda, approved by the FDA in January 2007 for induction of remission in ulcerative colitis. Its main benefit is that it needs to be taken only once a day, which improves convenience and treatment compliance.
Dosing depends on the preparation used, in particular, slow-release tablets may have quite different drug delivery characteristics and are not interchangeable.
Preparations that lower stool pH (such as lactulose, a laxative) will affect the binding of Mesalazine in the bowel and will therefore reduce its efficacy.

Side effects


Commonly:

★ Diarrhea

★ Nausea

★ Cramping
Uncommonly:

★ Headache

★ Exacerbation of the colitis

★ Hypersensitivity reactions (including rash, urticaria, interstitial nephritis and lupus erythematosus-like syndrome)

★ Hair Loss

Interstitial nephritis
Rarely:

★ Acute pancreatitis,

Hepatitis

Nephrotic syndrome

★ Blood disorders (including agranulocytosis, aplastic anaemia, leukopenia, neutropenia, thrombocytopenia)
Mesalazine avoids the sulphonamide side effects of Sulfasalazine (which contains additional (sulfapyridine), but carries additional rare risks of:

★ Allergic lung reactions

★ Allergic myocarditis

Methaemoglobinaemia

Monitoring


As a result of the small risks of kidney, liver and blood disorders, blood tests should be taken before and after starting treatment. Patients are advised to report any unexplained bleeding, bruising, purpura, sore throat, fever or malaise that occurs during treatment so that a full blood count can be urgently taken.

References



British National Formulary ''45'' March 2003

, , , , Pharmaceutical Press, , ISBN 0-85369-550-4

External links



Optimal Dosing of 5-Aminosalicylic Acid: 5 Decades of Choosing Between Politicians

"Novel formulation increases efficacy of mesalamine for treating ulcerative colitis" Reuters article on Lialda/Mezavant trial success.

This article provided by Wikipedia. To edit the contents of this article, click here for original source.